Compare Heron Therapeutics Inc (HRTX) vs Sezzle Inc (SEZL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Sezzle Inc — how do they compare? Heron Therapeutics Inc trades at $0.48 (market cap $91.46M), while Sezzle Inc trades at $178.42 (market cap $5.78B). The key difference: Sezzle Inc is far larger — about 63.2× Heron Therapeutics Inc's market cap, and Sezzle Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | SEZL | |
|---|---|---|
Market Cap | $91.46M | $5.78B |
Sector | Health | Technology |
52-Week High | $1.96 | $188.55 |
52-Week Low | $0.39 | $50.97 |
Enterprise Value | $189.36M | $5.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Sezzle (SEZL) trades at $171.76, down 1.67% today but maintaining strong momentum with consistent earnings beats and bullish technical indicators. The stock shows robust fundamentals with 30.83% net income margin and 91.95% ROE, though valuations remain elevated at P/E 41.72. Recent news highlights product expansion and strong Q1 2026 results, with the company scheduled to report Q2 earnings on August 6, 2026.
Outlook remains positive given earnings momentum and analyst consensus, but high valuation multiples and competitive fintech landscape pose risks. The stock trades above the $162 consensus target, suggesting near-term consolidation potential before potential upward revisions post-earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →
